{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:14:40Z","timestamp":1793247280295,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.drudis.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:58:58Z","timestamp":1635382738000},"page":"831-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management"],"prefix":"10.1016","volume":"27","author":[{"given":"Shihai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhining","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.drudis.2021.10.009_b0005","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.drudis.2021.10.009_b0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.009_b0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrd1108","article-title":"The impact of drug-induced QT interval prolongation on drug discovery and development","volume":"2","author":"Fermini","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.drudis.2021.10.009_b0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrcardio.2013.57","article-title":"Assessing cardiovascular drug safety for clinical decision-making","volume":"10","author":"Woosley","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.drudis.2021.10.009_b0025","unstructured":"ICH. E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. www.ema.europa.eu\/en\/ich-e14-clinical-evaluation-qtqtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic [accessed October 19, 2021]."},{"key":"10.1016\/j.drudis.2021.10.009_b0030","unstructured":"FDA Guidance for Industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. www.fda.gov\/media\/71372\/download. Published October; 2005 [accessed October 19, 2021]."},{"key":"10.1016\/j.drudis.2021.10.009_b0035","unstructured":"FDA Guidance for Industry. S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. www.fda.gov\/media\/72043\/download [accessed October 19, 2021]."},{"issue":"10","key":"10.1016\/j.drudis.2021.10.009_b0040","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrcardio.2009.154","article-title":"Cardiovascular pharmacogenomics and individualized drug therapy","volume":"6","author":"Pereira","year":"2009","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.drudis.2021.10.009_b0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cvr\/cvz013","article-title":"A current understanding of drug-induced QT prolongation and its implications for anticancer therapy","volume":"115","author":"Roden","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.drudis.2021.10.009_b0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","article-title":"CredibleMeds.org: what does it offer?","volume":"28","author":"Woosley","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.drudis.2021.10.009_b0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative - update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"16","key":"10.1016\/j.drudis.2021.10.009_b0060","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1111\/bph.13207","article-title":"Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance","volume":"172","author":"Vargas","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.009_b0065","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2021.10.009_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2015.06.003","article-title":"Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: conference report","volume":"76","author":"Klein","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2021.10.009_b0075","unstructured":"Code of Federal Regulations 201.56. Requirements on content and format of labeling for human prescription drug and biological products. https:\/\/ecfr.federalregister.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-201\/subpart-B [accessed October 19, 2021]."},{"key":"10.1016\/j.drudis.2021.10.009_b0080","unstructured":"Code of Federal Regulations 201.57. Specific requirements on content and format of labeling for human prescription drug and biological products described in \u00a7 201.56(b)(1). https:\/\/ecfr.federalregister.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-201\/subpart-B [accessed October 19, 2021]."},{"issue":"15\u201316","key":"10.1016\/j.drudis.2021.10.009_b0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","article-title":"FDA-approved drug labeling for the study of drug-induced liver injury","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.drudis.2021.10.009_b0090","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.drudis.2021.10.009_b0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drudis.2018.06.006","article-title":"Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management","volume":"24","author":"Wen","year":"2019","journal-title":"Drug Discov Today"},{"issue":"D1","key":"10.1016\/j.drudis.2021.10.009_b0100","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.drudis.2021.10.009_b0105","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jama.2021.1004","article-title":"Precision dosing: a clinical and public health imperative","volume":"325","author":"Maxfield","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.drudis.2021.10.009_b0110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","article-title":"COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives","volume":"17","author":"Nishiga","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"10.1016\/j.drudis.2021.10.009_b0115","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the American Heart Association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.10.009_b0120","unstructured":"FDA Drug Safety Communication. New risk management plan and patient medication guide for qualaquin (quinine sulfate). www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-new-risk-management-plan-and-patient-medication-guide-qualaquin [accessed October 19, 2021]."},{"issue":"2","key":"10.1016\/j.drudis.2021.10.009_b0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2008.04.008","article-title":"Off-label use of antiepileptic drugs for the treatment of neonatal seizures","volume":"39","author":"Silverstein","year":"2008","journal-title":"Pediatr Neurol"},{"issue":"15","key":"10.1016\/j.drudis.2021.10.009_b0130","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.drudis.2021.10.009_b0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.drudis.2021.10.009_b0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.2013.780026","article-title":"Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia","volume":"12","author":"Doggrell","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.drudis.2021.10.009_b0145","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00204-020-02952-7","article-title":"Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools","volume":"95","author":"Pang","year":"2021","journal-title":"Arch Toxicol"},{"issue":"9","key":"10.1016\/j.drudis.2021.10.009_b0150","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.drudis.2014.06.017","article-title":"Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling","volume":"19","author":"Warnier","year":"2014","journal-title":"Drug Discov Today"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621004475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621004475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:53:53Z","timestamp":1761224033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621004475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1359644621004475"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.10.009","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}